Experts divided on anticoagulant review

Experts have delivered mixed verdicts on the government’s review of anticoagulants, which kicks off this week, with one branding it “a waste of everybody’s time”.

The review comes amid controversy over the continued deferral of dabigatran (Pradaxa), which has been recommended for a PBS listing for stroke prevention in atrial fibrillation but is yet to receive one.

There have also been fresh question marks over the safety of